Trial Profile
A Phase I/Ib Open-label, Multi-center, Dose Escalation Study of GWN323 (Anti-GITR) as a Single Agent and in Combination With PDR001 (Anti-PD-1) in Patients With Advanced Solid Tumors and Lymphomas
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Dec 2021
Price :
$35
*
At a glance
- Drugs GWN 323 (Primary) ; Spartalizumab (Primary)
- Indications Lymphoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 20 Apr 2020 Status changed from active, no longer recruiting to completed.
- 13 Mar 2020 This trial is completed in Spain, accoeding to European Clinical Trials Database record.
- 06 Feb 2020 Planned End Date changed from 30 Nov 2019 to 1 Apr 2020.